Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyi-Sin Than

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Nutrition ESPEN|April 10, 2026
Quantifying the Lifetime Economic Impact of Pediatric Oral Nutritional SupplementsKyi-Sin Than, Khounish Sharma, Kirk W Kerr, et al.
Journal of Medical Economics|January 10, 2026
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-makingKyi-Sin Than, Jason Shafrin, Sanjana Muthukrishnan, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 31, 2023
Use of Conditionally Essential Amino Acids and the Economic Burden of Postoperative Complications After Fracture Fixation: Results from a Cost Utility AnalysisJason Shafrin, Kyi-Sin Than, Anmol Kanotra, et al.
Health Affairs Scholar|March 24, 2025
Use of real-world evidence in the Medicare Drug Price Negotiation Program: A checklist for the Centers for Medicare and Medicaid Services and manufacturersSean R Tunis, Jason Shafrin, Kyi-Sin Than, et al.
NPJ Genomic Medicine|November 23, 2021
The diagnostic trajectory of infants and children with clinical features of genetic diseaseBrock E Schroeder, Nina Gonzaludo, Katie Everson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2025
A Generalized Risk Adjusted Cost Effectiveness (GRACE) Economic Model for Measuring the Value of Interventions that Delay Mobility Impairment Across Neurological ConditionsJason Shafrin, Jaehong Kim, Jacob Fajnor, et al.
Forum for Health Economics & Policy|July 15, 2025
Two Approaches for Measuring Treatment Value Under Uncertainty: Estimating Insurance Value and Risk Preferences in NeurologyJason Shafrin, Kyi-Sin Than, Jacob Fajnor, et al.
Future Oncology (London, England)|October 21, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the USErin Mulvey, Jason Shafrin, Kyi-Sin Than, et al.
Breast (Edinburgh, Scotland)|July 23, 2022
Progression-free survival and quality of life in metastatic breast cancer: The patient perspectiveShirley Mertz, Christine Benjamin, Charis Girvalaki, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Nutrition ESPEN|April 10, 2026
Quantifying the Lifetime Economic Impact of Pediatric Oral Nutritional SupplementsKyi-Sin Than, Khounish Sharma, Kirk W Kerr, et al.
Journal of Medical Economics|January 10, 2026
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-makingKyi-Sin Than, Jason Shafrin, Sanjana Muthukrishnan, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 31, 2023
Use of Conditionally Essential Amino Acids and the Economic Burden of Postoperative Complications After Fracture Fixation: Results from a Cost Utility AnalysisJason Shafrin, Kyi-Sin Than, Anmol Kanotra, et al.
Health Affairs Scholar|March 24, 2025
Use of real-world evidence in the Medicare Drug Price Negotiation Program: A checklist for the Centers for Medicare and Medicaid Services and manufacturersSean R Tunis, Jason Shafrin, Kyi-Sin Than, et al.
NPJ Genomic Medicine|November 23, 2021
The diagnostic trajectory of infants and children with clinical features of genetic diseaseBrock E Schroeder, Nina Gonzaludo, Katie Everson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2025
A Generalized Risk Adjusted Cost Effectiveness (GRACE) Economic Model for Measuring the Value of Interventions that Delay Mobility Impairment Across Neurological ConditionsJason Shafrin, Jaehong Kim, Jacob Fajnor, et al.
Forum for Health Economics & Policy|July 15, 2025
Two Approaches for Measuring Treatment Value Under Uncertainty: Estimating Insurance Value and Risk Preferences in NeurologyJason Shafrin, Kyi-Sin Than, Jacob Fajnor, et al.
Future Oncology (London, England)|October 21, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the USErin Mulvey, Jason Shafrin, Kyi-Sin Than, et al.
Breast (Edinburgh, Scotland)|July 23, 2022
Progression-free survival and quality of life in metastatic breast cancer: The patient perspectiveShirley Mertz, Christine Benjamin, Charis Girvalaki, et al.
Pageof 1